DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

DexCom, Inc.

Dexcom develops and manufactures continuous glucose monitoring (CGM) systems for diabetes management.

Dexcom

Dexcom Corporation is a pioneer and global leader in continuous glucose monitoring (CGM).  Dexcom began as a small company with a big dream: To forever change how diabetes is managed. To unlock information and insights that drive better health outcomes. Here we are 25 years later, having pioneered an industry. And we're just getting started.  We are broadening our vision beyond diabetes to empower people to take control of health. That means personalized, actionable insights aimed at solving important health challenges. To continue what we've started: Improving human health. We are driven by over 10,000 ambitious, passionate people worldwide who are willing to fight like warriors to earn the trust of our customers by listening, serving with integrity, thinking big, and being dependable. We've already changed millions of lives and we're ready to change millions more.  Our future ambition is to become a leading consumer health technology company while continuing to develop solutions for serious health conditions. We'll get there by constantly reinventing unique biosensing-technology experiences. Though we've come a long way from our small company days, our dreams are bigger than ever. The opportunity to improve health on a global scale stands before us.

	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue	259.20M -	402M 55.09%	573.30M 42.61%	718.50M 25.33%	1.03B 43.58%	1.48B 43.08%	1.93B 30.54%	2.45B 27.08%	2.91B 18.84%	3.62B 24.49%
cost of revenue	82.90M -	123.60M 49.10%	194.90M 57.69%	226.40M 16.16%	367.70M 62.41%	544.50M 48.08%	646.60M 18.75%	768M 18.78%	1.03B 33.68%	1.33B 29.87%
gross profit	176.30M -	278.40M 57.91%	378.40M 35.92%	492.10M 30.05%	663.90M 34.91%	931.50M 40.31%	1.28B 37.42%	1.68B 31.28%	1.88B 12.06%	2.29B 21.55%
selling and marketing expenses
general and administrative expenses
selling general and administrative expenses	128.40M -	198M 54.21%	286.20M 44.55%	349.20M 22.01%	432.80M 23.94%	515.70M 19.15%	620.70M 20.36%	810.50M 30.58%	1.00B 23.41%	1.19B 18.52%
research and development expenses	69.40M -	137.50M 98.13%	156.10M 13.53%	185.40M 18.77%	417.40M 125.13%	273.50M 34.48%	359.90M 31.59%	604.20M 67.88%	484.20M 19.86%	505.80M 4.46%
other expenses			-700K -	3.40M 585.71%				-1.70M -	7.50M 541.18%	-3.90M 152%
cost and expenses	280.70M -	459.10M 63.56%	637.20M 38.79%	761M 19.43%	1.22B 60.04%	1.33B 9.51%	1.63B 22.01%	2.18B 34.14%	2.52B 15.39%	3.02B 20.09%
operating expenses	197.80M -	335.50M 69.62%	442.30M 31.83%	534.60M 20.87%	850.20M 59.03%	789.20M 7.17%	980.60M 24.25%	1.41B 44.27%	1.49B 5.46%	1.69B 13.36%
interest expense	800K -	400K 50%	700K 75%	12.80M 1,728.57%	22.70M 77.34%	60.30M 165.64%	84.70M 40.46%	102M 20.43%	18.60M 81.76%	20.30M 9.14%
ebitda	-21.50M -	-57.10M 165.58%	-64.20M 12.43%	-35.80M 44.24%	-103.80M 189.94%	164.50M 258.48%	382.70M 132.64%	277.40M 27.52%	416.90M 50.29%	916.70M 119.88%
operating income	-21.50M -	-57.10M 165.58%	-63.90M 11.91%	-42.50M 33.49%	-186.30M 338.35%	142.30M 176.38%	299.50M 110.47%	175.40M 41.44%	391.20M 123.03%	597.70M 52.79%
depreciation and amortization	8.40M -	10.80M 28.57%	15M 38.89%	16.10M 7.33%	29.10M 80.75%	22.20M 23.71%	83.20M 274.77%	102M 22.60%	25.70M 74.80%	186M 623.74%
total other income expenses net	-800K -	-400K 50%	-700K 75%	3.40M 585.71%	80.10M 2,255.88%	-38.10M 147.57%	-74.50M 95.54%	-1.50M 97.99%	-400K 73.33%	-2M 400%
income before tax	-22.30M -	-57.50M 157.85%	-64.90M 12.87%	-48.60M 25.12%	-126.50M 160.29%	104.20M 182.37%	225M 115.93%	173.90M 22.71%	390.80M 124.73%	710.40M 81.78%
income tax expense	100K -	100K 0%	700K 600%	1.60M 128.57%	600K 62.50%	3.10M 416.67%	-268.60M 8,764.52%	19.20M 107.15%	49.60M 158.33%	168.90M 240.52%
net income	-22.40M -	-57.60M 157.14%	-65.60M 13.89%	-50.20M 23.48%	-127.10M 153.19%	101.10M 179.54%	493.60M 388.23%	154.70M 68.66%	341.20M 120.56%	541.50M 58.70%
weighted average shs out	300.80M -	319.20M 6.12%	334.40M 4.76%	345.20M 3.23%	352.80M 2.20%	364.40M 3.29%	377.60M 3.62%	386.90M 2.46%	389.40M 0.65%	386M 0.87%
weighted average shs out dil	300.80M -	319.20M 6.12%	334.40M 4.76%	345.20M 3.23%	352.80M 2.20%	369.20M 4.65%	390M 5.63%	428.80M 9.95%	427.50M 0.30%	425.50M 0.47%
eps	-0.07 -	-0.18 141.61%	-0.20 11.11%	-0.15 25.00%	-0.36 140%	0.28 177.78%	1.31 367.86%	0.56 57.25%	0.88 57.14%	1.40 59.09%
epsdiluted	-0.07 -	-0.18 141.61%	-0.20 11.11%	-0.15 25.00%	-0.36 140%	0.28 177.78%	1.26 350.00%	0.53 57.94%	0.82 54.72%	1.30 58.54%

COM:DEXCOM

Dexcom

Last Close

79.51

07/03 21:00

Market Cap

44.06B

Beta: -

Volume Today

3.88M

Avg: -

Preview